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Tuberculosis is one of the leading causes of morbidity and mortality worldwide. The World Health Organization estimated that in 2015 there were an estimated 10.4 million incident TB cases, and 1.4 million deaths from TB, and an additional 0.4 million deaths associated with coinfection with HIV (WHO, 2016) . The comorbidity of TB and other diseases requires treatment with multiple medications. Understanding of potential drug-drug interactions (DDIs) is of importance in planning safe and effective combination therapies.
Isoniazid, rifampicin (or rifampin), pyrazinamide, ethambutol, rifabutin, and rifapentine are the principal first-line anti-TB drugs to treat drug-susceptible tuberculosis (Zumla et al., 2013) .
Bedaquiline is a novel anti-mycobacterial agent which was approved by FDA in 2012 to treat multidrug resistant tuberculosis (Worley et al., 2014) . Among those, rifampicin is a potent inducer of CYPs and UGTs, as well as the P-glycoprotein transport system both in vitro (Rae et al., 2001; Soars et al., 2004) and clinically (Baciewicz et al., 2013) . Rifampicin is reported also to be an inhibitor of some human CYPs in vitro (Kajosaari et al., 2005) , but its overall effect is enzymatic induction, reducing systemic concentrations of many drugs (Ochs et al., 1981) .
Compared to rifampicin, rifabutin has less potency as a CYP3A inducer and is used as a substitute for rifampicin in patients receiving protease inhibitor and integrase inhibitor-based antiretroviral therapy (Zumla et al., 2013; Baciewicz et al., 2013; WHO, 2010) . Isoniazid is known as an inhibitor of many human CYPs in vitro (Wen et al., 2002; Polasek et al., 2004) and clinically (Ochs et al., 1981; Ochs et al., 1983) .
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5 Both the inductive effects of rifampicin and inhibitory effects of isoniazid on human CYPs have been extensively reported in vitro and in vivo. However, the data of their effects on human UGTs is limited. Furthermore, the information on other anti-TB drugs is also limited. In this work, inhibitory effects of isoniazid and rifampicin on human hepatic UGTs were studied; and inhibitory properties of the selected anti-TB drugs, including pyrazinamide, ethambutol, rifabutin, and bedaquiline were also studied in vitro with human hepatic CYP and UGT enzymes.
Acetaminophen is widely used as an analgesic and antipyretic agent. Since APAP glucuronidation is the pathway responsible for converting two-thirds of a dose of APAP into non-toxic glucuronide conjugates, we also evaluated the inhibitory effect of the anti-TB drugs on acetaminophen glucuronidation. Procurement and Distribution System, University of Minnesota (Minneapolis, MN, USA), or the National Disease research Interchange (Philadelphia, PA, USA). HLMs were prepared as previously described (Greenblatt et al., 2011; von Moltke et al., 1993a) . Fifty-three individual liver microsomal preparations were combined to make a batch of pooled HLMs, by mixing an equal amount of protein from each HLM.
Materials and Methods

Chemicals
Inhibition Studies on CYP-mediated Oxidation Using HLMs. Previously published incubation procedures using HLMs (Greenblatt et al., 2011; von Moltke et al., 2001; Sonnichsen et al., 1995; Giancarlo et al., 2001; Hesse et al., 2000) were used with modifications. Briefly, appropriate substrates and positive controls (Table 1) were added to incubation tubes. The anti-TB drugs were individually added in a series of concentrations to separate incubation tubes.
Isoniazid, rifampicin, pyrazinamide, and ethambutol were at concentrations of 0, 10, 60, 100, 200, 400, 600 and 1000 µM; rifabutin was at concentrations of 0, 10, 60, 100, 200, 400, and 600 µM, except for CYP2C9 and 2D6 with an extra concentration of 1000 µM; and bedaquiline was at concentrations of 0, 0.78, 1.56, 3.13, 6.25, 12.5, 20 and 25 µM. The solvent (methanol) was evaporated to dryness at 40°C under mild vacuum conditions. Due to their poor solubility in methanol, propofol (the UGT1A9 substrate) and bedaquiline were prepared in DMSO and added directly to incubation tubes (1% DMSO v/v). Methanol at 1% (v/v) in the final incubation mixture was added to reconstitute the anti-TB compounds (except for bedaquiline) after dryness.
The incubation mixtures for CYP-mediated oxidation contained 50 mM phosphate buffer (pH 7.5), 5 mM MgCl 2 , 0.5 mM NADP, isocitrate and an isocitric dehydrogenase regenerating 
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7 system, and appropriate amounts of the pooled HLMs. The anti-TB drugs were preincubated with HLMs (without the index substrates) for 20 minutes at 37°C, and then followed by another timed incubation with the substrates (250μL). All incubations were performed in duplicate.
Initial tests for detecting IC 50 shifts were carried out by comparing incubations with 20 minutes' preincubation to incubations without preincubation. 100 µL of acetonitrile (or acidified acetonitrile adjusted with 85% H 3 PO 4 for CYP2B6 and 2C9) with internal standards was used to stop the reactions. After centrifugation, the supernatant was transferred to HPLC vials for HPLC-UV or HPLC-fluorescence analysis.
Inhibition Studies on Glucuronidation Using HLMs. Previously described incubation procedures were used with modifications (von Moltke et al., 1993b; Court, 2010; Court, 2005) .
The incubation mixtures for the glucuronidation studies were prepared with 50 mM phosphate buffer (pH 7.5), 5 mM MgCl 2 , alamethicin (50 µg per mg protein), and appropriate amounts of the pooled HLMs. The mixtures were kept on ice for 5 minutes before use. UDPGA was freshly prepared separately in the phosphate buffer. The reactions were initiated by addition of the UDPGA solution (a final concentration of 10 mM) in the incubation mixtures (100uL). All incubations were performed in duplicate. The incubations were conducted without preincubation except for those with β-estradiol (UGT1A1), trifluoperazine (UGT1A4), and APAP, for which the incubations with 20 minutes' preincubation were also conducted. The reactions were stopped by adding 40 µL of acetonitrile (or acidified acetonitrile adjusted with 85% H 3 PO 4 for UGT2B7 and APAP glucuronidation) with internal standards to the incubation mixtures. After centrifugation, the supernatant was transferred to HPLC vials for HPLC-UV analysis.
This article has not been copyedited and formatted. The final version may differ from this version. observed with an IC 50 value of 11 µM, which is low enough to trigger a DDI concern. As there was no IC 50 shift with and without preincubation, the experimental design for reversible enzymatic inhibition (Greenblatt et al., 2011) was applied to determine the K i value for rifabutin versus human UGT1A4 using pooled HLMs. Varying concentrations of the index substrate (trifluoperazine) at 0, 2, 5, 10, 20, 34.2, 72.4, 144.9 and 336.6 µM were incubated at 37°C with pooled HLMs in presence of varying concentrations of the inhibitor (rifabutin), at 0, 1.25, 5, 10, 30, and 60 µM respectively. Probenecid at 2.4 mM was used as the positive inhibitory control.
After 30 minutes' incubation, the reactions were stopped with 40 µL of acetonitrile (in the incubation mixtures of 100 µL) with the internal standard (phenacetin). After centrifugation, the supernatant was transferred to HPLC vials for HPLC-UV analysis.
Analytical Methods
Previously described methods, with modifications were used for analysis of the in vitro samples in this study Court, 2005) . The HPLC conditions and detection methods are summarized (Supplemental Table 1 ). APAP glucuronide generated from the in vitro incubations was analyzed using the previously described method, with modifications (Zhao et al., 2015) . Briefly, the HPLC analysis was carried out using a Hydro-RP column (4 μm, 250x4.6 mm, Synergi Hydro-RP, Phenomenex, Torrance, CA), with a flow rate of 1.2 mL/min. The injection volume was 30 µL, and the UV detection wavelength was 254 nm. A multistep gradient was started at 96.5% mobile phase A (20 mM potassium phosphate buffer, pH 2.2) and 3.5% mobile phase B (methanol) for 5 minutes, increased to 16% B during the next 5 minutes, and reached 20% B at 15 minutes, then to 40% B at 30 minutes, followed by a 9 minutes' This article has not been copyedited and formatted. The final version may differ from this version. 
DMD # 76034
9 isocratic run at 100% mobile phase C (50% H 2 O, 50% methanol), followed by another 10 minutes' isocratic run at 3.5% B. The integration and quantitation were done with the software Chemistation (Agilent, Santa Clara, California).
Data Analysis
IC 50 Values. IC 50 values were determined using nonlinear regression as described previously (Greenblatt et al., 2011; von Moltke et al., 2001 ). Sigmaplot 11.0 was applied for the nonlinear regression procedure. Briefly, the relationships between the formation of the metabolites of the substrates and the inhibitory concentrations of the tested anti-TB drugs were analyzed by nonlinear regression fitting using Equation 1. The IC 50 values were then generated from the IC values using Equation 2 in order to take into consideration the possibility of incomplete
R is the formation rate of the metabolite of interest, expressed as a percentage fraction of the control reaction velocity with no inhibitor; E max , the maximum degree of inhibition; [I] , the concentration of the anti-TB drugs; b, an exponent; IC, the inhibitor concentration producing an R value of 50% of (100-E max ), as determined from the nonlinear regression procedure; IC 50, the concentration of the tested anti-TB drugs producing 50% inhibition compared to the inhibitorfree control value, as calculated from the IC value using Equation 2.
This article has not been copyedited and formatted. The final version may differ from this version. was determined by nonlinear regression using the reversible inhibition model of full competitive inhibition (Greenblatt et al, 2011) on Sigmaplot 13.0. Significant substrate inhibition of trifluoperazine was observed at the concentration of 336.6 μM in our study, as reported previously (Uchaipichat et al., 2006) . Thus, the reversible model of full competitive inhibition was fitted using concentrations of trifluoperazine up to 144.9 μM.
Results
IC 50
Values for Rifabutin on Human Hepatic CYPs. Rifabutin inhibited human CYP3A, 2B6, 2D6, 1A2, 2C8 and 2C9 to varying degrees in vitro using the pooled HLMs (Table 2 , Fig.   1 ). At the highest tested concentration (600 μM), no inhibition of human CYP2E1 or 2C19 was observed in vitro with rifabutin ( Fig. 1 Fig. 2 and 3), and partially inhibited human UGT1A9 and 2B7 (Table 2 , Fig. 2 ) at a high concentration of 600 μM. The IC 50 values for rifabutin on human hepatic UGT1A4 were 10.8 and 11.3 μM respectively, for the incubations with and without preincubation. The K i value for rifabutin on UGT1A4 using trifluoperazine as the index substrate was 2 μM, with the pattern of inhibition consistent with reversible competitive inhibition (Fig. 4) .
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 3) ; partial inhibition of human UGT1A6 was observed at the highest tested concentration (1000 μM) (Fig. 2) . No inhibitory effects of isoniazid were observed up to the highest tested concentration (1000 μM) (Fig. 2) .
Inhibitory Effects of Pyrazinamide, Ethambutol and Bedaquiline on Human Hepatic CYPs
and UGTs. Up to the highest tested concentration (1000 μM), no significant inhibitory effects of pyrazinamide or ethambutol were observed on the 8 screened CYPs (Table 2 ) or 6 UGTs ( Fig.   2 ). At the highest tested concentration (25 μM), bedaquiline partially inhibited human hepatic CYP3A, 2B6, 2C8, 2C19 and 2D6 at varied levels, but inhibition did not exceed 50% of the control metabolite formation rate (Fig. 2) . 
Inhibitory Effects of
Discussion
Rifabutin inhibited human CYP3A, 2B6, 2C8, 2D6, 1A2, 2C9, UGT1A1, 2B15, UGT1A9 and 2B7 in HLMs, with varying inhibitory potency. However, most of those inhibitory effects (Peloquin, 2002; Skinner, 1989 (Skinner, 1989) and K i was 2 μM in this estimation. The ratio of 0.55 indicates a possibility that rifabutin may increase the systemic exposure of some drugs which are metabolized mainly by human UGT1A4. On the other hand, it has been widely reported that rifabutin induces human CYPs and UGTs (Baciewicz et al., 2013) . Thus the prediction of the overall drug-drug interaction of rifabutin needs to consider both its inhibitory and possible inductive properties.
Human UGT1A1 is the principal metabolizing enzyme for several anti-HIV drugs such as raltegravir (Kassahun et al., 2007) and dolutegravir (Castellino et al., 2013) . The IC 50 values for rifabutin and rifampicin on UGT1A1 were approximately 35 μM and 70 μM respectively (Fig.   3) . However, the inhibitory effects of rifabutin and rifampicin are not of major clinical importance, as their overall effects show predominantly inductive properties. In clinical studies, rifampicin significantly decreased the systemic exposure of dolutegravir (Dooley et al., 2013) .
Co-administration of rifabutin, on the other hand, did not alter the pharmacokinetics of raltegravir (Brainard et al., 2011) or dolutegravir (Dooley et al., 2013) .
This article has not been copyedited and formatted. The final version may differ from this version. 1 ). We did not determine the rate constant for inactivation in this study. Nevertheless, to our knowledge, no clinically meaningful DDIs due to inhibition of CYP1A2 by rifabutin have been reported.
The lack of significant inhibition of UGTs by isoniazid is reassuring for the use of isoniazid for latent TB treatment in HIV-infected patient receiving integrase strand transfer inhibitors (INSTIs)-based antiretroviral therapy. Isoniazid for 6 or 9 months is one of the preferred regimens for the treatment of latent TB (Getahun et al, 2015) . The INSTIs such as dolutegravir, raltegravir or elvitegravir that are primarily metabolized by UGTs are essential components of preferred first-line antiretroviral therapy for HIV infection (Günthard et al., 2016) . The findings in this in vitro study suggest that no dose adjustment of the INSTIs is necessary when coadministered with isoniazid, although in vivo studies may be needed to confirm this.
Incomplete inhibition was observed for a number of the CYP and UGT isoforms in this study.
This might be explained by the participation of multiple isoforms in a given biotransformation pathway, particularly if the substrate is not specific for the target enzyme isoform of interest.
The incomplete inhibition in Figure 5B and 5C could be explained by this. However, the explanation for incomplete inhibition in Figure 3E is not clear, since the substrate trifluoperazineis reported to be highly specific for UGT1A4 (Uchaipichat et al., 2006) . In addition, the incomplete inhibition was only observed with rifampicin but not with rifabutin. In any case, the calculated IC 50 values correctly represent the inhibitor concentration that reduces 
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14 the metabolite formation to 50% of the inhibitor-free control value (fixed at 100%). In the scenario of incomplete inhibition (E max less than 1.0 in Equation 1), the true IC 50 is calculated from IC using Equation 2.
Since high concentrations of the anti-TB drugs were used in the incubations, 1% methanol was introduced to improve solubility. Bedaquiline was prepared in DMSO for better solubility and added directly to the incubation mixtures. Because methanol and DMSO may themselves inhibit metabolic activities of CYPs and UGTs, inhibitor-free controls were included using the same concentrations of these solvents to control for any solvent effects that might occur.
Acetaminophen is a common over-the-counter analgesic and antipyretic. The CYP mediated oxidation pathway produces the toxic intermediate N-acetyl-p-benzoquinone imine (Miner and Kissinger, 1979) , known to be responsible for acetaminophen hepatotoxicity. Parallel glucuronidation and sulfation of APAP are the major metabolizing pathways for generation of non-toxic metabolite conjugates. Several UGTs, including UGT1A1, 1A6, 1A9 and 2B15 are involved in APAP glucuronidation. (Court et al., 2001; Court and Greenblatt, 2000; Krishnaswamy et al., 2005; Mutlib et al., 2006) . None of the selected anti-TB drugs significantly inhibited glucuronidation of APAP in vitro in this study (Fig. 5) ..
In conclusion, this study provides data on the inhibitory effects of anti-TB drugs on common Table 2 . values were determined by non-linear regression and summarized in Table 2 . The concentrations of rifampicin are 0, 8, 47.7, 79.6, 159.1, 318.3, 477.4 and 795.7 
